About Roland Buelow

Dr. Buelow has worked in biotechnology for almost thirty years and has extensive pharmaceutical experience. He is the founder and CEO of Teneobio. Dr. Buelow was founder and CEO of Open Monoclonal Technology, Inc. which developed OmniRat, OmniFlic, Omnimouse and UniRat and was acquired by Ligand Pharmaceuticals in 2015. Dr. Buelow was a founder of THP, Inc., a biotechnology company which engineered rabbits to produce human antibodies and was acquired by Roche in March 2007. Between 1993 and 2003, Dr. Buelow was senior vice president of research and development at SangStat Medical Corporation, where he developed RDP58, an anti-inflammatory compound that demonstrated efficacy in a placebo-controlled, blinded Phase II study in ulcerative colitis patients. During his scientific career at the Eberhard-Karls-University Tuebingen, the University of Texas at Austin, the Max-Planck-Institute, Stanford University and in biotech Dr. Buelow published more than 100 manuscripts and is an inventor on more than 30 patents